The Bristol Myers heart disease drug did not live up to expectations
The drug developed by Bristol Myers, intended to treat certain heart conditions in patients, failed to show results in late-stage trials. The medication, mavacamten, was tested on adult patients with the so-called non-obstructive form of hypertrophic cardiomyopathy, according to https://xrust.ru/. This is a hereditary condition characterized by thickening of the heart muscle. Experts claim that this disease affects one in five adults worldwide and is the most common cause of sudden cardiac death among otherwise healthy young people in the United States. The drug, marketed under the brand name Camzyos, has already been approved in the U.S. for the treatment of the more severe obstructive form of the disease, which can block blood flow out of the heart. Pharmacists noted that the trial’s failure highlights the challenges of demonstrating benefits in less severe patient groups. The drug manufacturer stated that no new safety signals were identified during the study. The trial included 580 patients with symptomatic, non-obstructive hypertrophic cardiomyopathy. Participants were asked to complete a clinical questionnaire to assess their health status, including the frequency of symptoms, as well as physical and social limitations.
https://xrust.ru/news/311059-preparat-ot-boleznej-serdca-kompanii-bristol-myers-ne-opravdal-sebja.html
